AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Alpha-protein kinase 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q96QP1

UPID:

ALPK1_HUMAN

Alternative names:

Chromosome 4 kinase; Lymphocyte alpha-protein kinase

Alternative UPACC:

Q96QP1; B4E3G1; F5H138; Q68CI9; Q6P9F9; Q6ZNK4; Q9P201

Background:

Alpha-protein kinase 1, also known as Chromosome 4 kinase and Lymphocyte alpha-protein kinase, plays a pivotal role in the innate immune response. It detects bacterial pathogen-associated molecular pattern metabolites, initiating critical steps for pathogen elimination and adaptive immunity engagement. This kinase specifically recognizes ADP-D-glycero-beta-D-manno-heptose, a potent PAMP present in various bacteria, stimulating kinase activity for pro-inflammatory signaling.

Therapeutic significance:

Alpha-protein kinase 1's involvement in Retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache syndrome highlights its potential as a therapeutic target. Understanding the role of Alpha-protein kinase 1 could open doors to potential therapeutic strategies for this complex disorder.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.